Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Audioconference: Management of Fibromyalgia

Staff  |  February 1, 2007

Tremendous progress is being made in the area of fibromyalgia,” says Dan Clauw, MD, professor of medicine in the division of rheumatology at the University of Michigan in Ann Arbor and moderator of the March 14 audioconference on the current management of fibromyalgia. “However,” he continues, “as in many fields of medicine, those who are not directly involved in fibromyalgia research and treatment are not aware of the progress that has been made.”

Filed under:ConditionsEducation & TrainingFrom the CollegePain SyndromesResearch RheumSoft Tissue Pain Tagged with:EducationFibromyalgiapatient careResearchrheumatologistTreatment

Office Visit

Heather Lindsey  |  January 1, 2007

A Day in the Life of Niveditha Mohan, MD

Filed under:Profiles Tagged with:patient carerheumatologistrural

JAK Inhibitors 101

Jason Liebowitz, MD, FACR  |  July 28, 2025

Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherGuidanceMeeting Reports Tagged with:EULAR 2025JAK inhibitorsJanus Kinase Inhibitors

Finding the Panacea

Jason Liebowitz, MD, FACR  |  July 16, 2025

Janus kinase (JAK) inhibitors, biologics and more—Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:Axial Psoriatic Arthritis (axPsA)EULAR 2025PsAPsA Resource CenterPsoriatic Arthritisskin

B Original: B Cells, Non-Invasive Biomarkers & More

Jason Liebowitz, MD, FACR  |  July 15, 2025

Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:B cellsEULAR 2025Lupus nephritismitochondriaskinSLESLE Resource Centersystemic lupus erythematosus (SLE)

CMS to Implement AI-Based Model to Streamline Prior Authorization

From the College  |  July 7, 2025

Last week, the Centers for Medicare & Medicaid Services (CMS) announced that it is implementing a new prior authorization model called the Wasteful and Inappropriate Services Reduction (WISeR) Model. This six-year model, starting on Jan. 1, 2026, aims to reduce fraud, waste and abuse in traditional Medicare by using technology-enabled processes for prior authorization and…

Filed under:American College of RheumatologyBilling/CodingPractice Support Tagged with:Wasteful and Inappropriate Services Reduction (WISeR) Model

Reactive Arthritis: Chronic or Self-Limiting?

Michael J. Cammarata, MD  |  June 8, 2025

Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.

Filed under:Axial SpondyloarthritisConditions Tagged with:biologic DMARDsdisease managementextra-articular manifestationsGlucocorticoidsHLA-B27infectious etiologymusculoskeletal manifestationsNSAIDsReactive arthritisspondyloarthritissulfasalazine

One Rheumatologist’s Sabbatical for Contemplative Leisure

Daniel F. Battafarano, DO, MACP, MACR  |  June 7, 2025

The year before my hike, I was extremely busy with various ACR workforce issues; meetings; presentations, locally, regionally and nationally; juggling medical missions and more. However, I had blocked time in my calendar over one year in advance to hike the Camino de Santiago in Spain with a long-time U.S. Army buddy. I met Pat…

Filed under:CareerOpinionSpeak Out Rheum Tagged with:burnoutMental HealthPhysical Therapyphysician well-beingself-carestress reductionwellnesswork-life balance

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

New Discoveries in Sjögren’s Disease

Vanessa Caceres  |  June 1, 2025

Although dryness and other symptoms of Sjögren’s disease continue to vex patients, the prospect of new treatments and a recent name change demonstrate advances in patient care.

Filed under:ConditionsSjögren’s Disease Tagged with:ACR on AirACR on Air podcastDry eyeeyemouthpatient careSjogren'sskin

FDA Approvals: Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2025

Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:belimumabFDA approvalLupus nephritis supplementvoclosporin

  • « Previous Page
  • 1
  • …
  • 62
  • 63
  • 64
  • 65
  • 66
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences